小狗Rosie走了三个月后，她的病历变成了一家AI医疗公司

TL;DR - AI-assisted veterinary oncology startup Gamgee raised a $4 million seed round to industrialize personalized mRNA cancer vaccines for dogs, building on an experimental treatment created for founder Paul Conyngham’s dog Rosie. The funding will support a clinical trial, as the approach’s efficacy remains unproven beyond the individual case.

• The workflow sequences tumor and healthy tissue, identifies tumor-specific mutations and neoantigens, and designs a personalized mRNA vaccine for each dog.
• Rosie’s design reportedly used tools including ChatGPT, AlphaFold, and Grok, but university researchers reviewed the data and manufactured the vaccine.
• Gamgee aims to shorten and coordinate the full treatment pipeline—from veterinary intake and sequencing through production, dosing, and follow-up—not merely the AI design stage.
• Australian clinical studies will determine whether the N-of-1 approach produces evidence acceptable to veterinarians and regulators; Rosie’s temporary remission alone is not sufficient proof.